Clinical trials: NAMD
Age-related Macular Degeneration
Study to Assess the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen (TALON)
This was a 64-week randomized, double-masked, multi-center, active-controlled, two-arm study in patients with neovascular age related macular degeneration (nAMD) who have not previously received anti- vascular endothelial growth…
- Trial name
- TALON (NCT04005352)
- Testing
- Brolucizumab 6 mg, Aflibercept 2 mg
- Where
- 118 sites in United States, Argentina and 18 more
- Volunteers
- 734 people
- Sponsor
- Novartis Pharmaceuticals
Neovascular Age-Related Macular Degeneration (nAMD)
Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With nAMD
This is a prospective study designed to evaluate the long-term safety and efficacy of ABBV-RGX-314. Eligible participants are those who were previously enrolled in a clinical study of nAMD in which they received suprachoroidal…
- Trial name
- NCT05210803
- Testing
- Standard of Care, Ranibizumab
- Where
- 16 sites in United States
- Volunteers
- 116 people
- Sponsor
- AbbVie
Retinal Vasculitis
A Real-World Evidence Study for the Incidence of Retinal Vasculitis (RV) Among Adult Patients Receiving Aflibercept 2 mg in the United States (US)
This study will describe and estimate the incidence of RV events among patients and patient eyes receiving aflibercept intravitreal (IVT) (Eylea® 2mg) therapy in US clinical practice.
- Trial name
- NCT06769412
- Testing
- aflibercept 2 mg
- Where
- United States
- Volunteers
- 550,000 people
- Sponsor
- Regeneron Pharmaceuticals
Central Serous Chorioretinopathy, Age Related Macular Degeneration
PRedictive Factors and Changes From Treatment in iPCV Versus CSR Versus nAMD With afLibercept
The presence of PEDs in nAMD, CSR and iPCV can present a diagnostic challenge in the elderly population; despite detailed diagnostic testing to differentiate these three conditions, misdiagnosis and mistreatment still occurs.
- Conditions
- Central Serous Chorioretinopathy, Age Related Macular Degeneration, Idiopathic Poplypoidal Choroidal Vasculopathy
- Trial name
- PRaCTICAL (NCT02681783)
- Testing
- aflibercept
- Where
- Canada
- Volunteers
- 90 people
- Sponsor
- Sunnybrook Health Sciences Centre
Neovascular Age-Related Macular Degeneration (nAMD)
RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD)
This interventional study is being conducted with an investigational gene therapy treatment called ABBV-RGX-314 (also known as RGX-314) and is being developed as a potential one-time gene therapy treatment for neovascular (wet)…
- Trial name
- AAVIATE (NCT04514653)
- Testing
- Ranibizumab, ABBV-RGX-314 Dose 1, ABBV-RGX-314 Dose 2
- Where
- 18 sites in United States
- Volunteers
- 146 people
- Sponsor
- AbbVie
Neovascular Age-related Macular Degeneration
Effectiveness of Brolucizumab in Pre-treated Patients With nAMD in the Real-world Setting
The study is a prospective and retrospective, observational, single-arm, non-randomized cohort study of ocular treatment with intravitreal injections of brolucizumab in nAMD patients.
- Trial name
- NCT05266495
- Testing
- Brolucizumab
- Where
- United Arab Emirates
- Volunteers
- 3 people
- Sponsor
- Novartis Pharmaceuticals
Wet Age-related Macular Degeneration (wAMD)
High Dose (HD) Aflibercept Switch in Neovascular Age-related Macular Degeneration (nAMD): to Load or Maintain (HEIRLOOM)
The purpose of this study is to compare two treatment frequencies using EYLEA® HD (aflibercept 8mg) in patients with wet age-related macular degeneration (wAMD) that are currently treated with EYLEA® (aflibercept 2mg).
- Trial name
- HEIRLOOM (NCT07129239)
- Testing
- Maintenance
- Where
- Canada
- Volunteers
- 180 people
- Sponsor
- Clinique de Retine de l'est
Age-related Macular Degeneration
Head to Head Study of Anti-VEGF Treatment.
An exploratory single site, open label, randomized, controlled study evaluated plasma vascular endothelial growth factor levels after intravitreal injection of ranibizumab (Lucentis) and conbercept (Langmu) for neovascular…
- Trial name
- RELIANCE (NCT02577107)
- Testing
- ranibizumab, Conbercept
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Novartis Pharmaceuticals
Neovascular Age-related Macular Degeneration (nAMD), Diabetic Macular Edema (DME), Retinal Vein Occlusion (RVO)
DATA-INSIGHT is a Project That Looks at Health Data in Germany to Find Out How Many Patients Suffer From Eye Disease. The Project Also Explores New Ways to Collect and Use Publicly Available Healthcare Information.
The main goal of this study is to find out how common certain eye diseases are in Germany and how they have changed over time. The diseases being studied are: nAMD (neovascular age-related macular degeneration): a condition that…
- Trial name
- NCT07308639
- Testing
- anti-VEGF medication
- Where
- Germany
- Volunteers
- 50,000 people
- Sponsor
- Bayer
Presence of Retinal Fluid, Changes in Macular Pigment Optical Density
Aflibercept 8 mg for nAMD: Early Anatomical and Functional Changes
Neovascular age-related macular degeneration (nAMD) is one of the main causes of irreversible vision loss in older people worldwide.
- Trial name
- NCT07074054
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- Federico II University
Neovascular Age-related Macular Degeneration, Wet Age-related Macular Degeneration
Safety and Tolerability of RGX-314 (Investigational Product) Gene Therapy for Neovascular AMD Trial
Excessive vascular endothelial growth factor (VEGF) plays a key part in promoting neovascularization and edema in neovascular (wet) age-related macular degeneration (nAMD).
- Trial name
- NCT03066258
- Testing
- RGX-314
- Where
- 8 sites in United States
- Volunteers
- 42 people
- Sponsor
- REGENXBIO Inc.
Neovascular Age-Related Macular Degeneration
Russian Registry of Patients With nAMD
A three-year, non-randomized, observational, multicenter prospective nAMD study - patient registry.
- Trial name
- NCT04935411
- Testing
- nAMD
- Where
- Russia
- Volunteers
- 2,665 people
- Sponsor
- Novartis Pharmaceuticals
AMD, nAMD
Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD
ABBV-RGX-314 (also known as RGX-314) is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (wet AMD or nAMD).
- Conditions
- AMD, nAMD, Wet Age-related Macular Degeneration, wAMD
- Trial name
- ATMOSPHERE (NCT04704921)
- Testing
- ABBV-RGX-314, Ranibizumab (LUCENTIS®)
- Where
- 89 sites in United States
- Volunteers
- 671 people
- Sponsor
- AbbVie
Diabetic Macular Edema (DME), Neovascular Age-Related Macular Degeneration (nAMD)
Study to Evaluate an 8 mg Aflibercept (EYLEA®) Prefilled Syringe (PFS)
Regeneron Pharmaceuticals developed a single-dose pre-filled syringe (PFS) to deliver 8 mg aflibercept. The PFS is a convenient device that contains the study medication that will be injected in your study eye.
- Trial name
- NCT05989126
- Testing
- aflibercept 8 mg PFS
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- Regeneron Pharmaceuticals
Exudative Macular Degeneration
Treatment of Neovascular AMD: Artificial Intelligence in Real-world Setting
The purpose of this study is to implement quantitative assessment tools for the treatment of active neovascular AMD patients in a real-world setting in order to provide advantages for both patients (treatment burden) and…
- Trial name
- NCT05093374
- Testing
- anti-VEGF agent
- Where
- Austria
- Volunteers
- 290 people
- Sponsor
- Medical University of Vienna
AMD
Quality-Assured Follow-up of Quiescent Neovascular Age -Related maculaR dEgeneration by Non-medical Practitioners
This is a prospective, randomised, multi-site clinical trial testing the non-inferiority of community optometry follow-up of participants with QnAMD over 12 months
- Trial name
- FENETRE (NCT03893474)
- Testing
- OCT, Visual Acuity
- Where
- United Kingdom
- Volunteers
- 742 people
- Sponsor
- Moorfields Eye Hospital NHS Foundation Trust
nAMD
Safety and Efficacy Study of IVB103 Injection in Subjects With Neovascular (Wet) Agerelated Macular Degeneration (nAMD).
The goal of this clinical trial is to evaluate the safety and efficacy of IVB103 injection in subjects with nAMD.
- Trial name
- NCT06737354
- Testing
- IVB103 Injection（Low dose）, IVB103 Injection（Intermediate dose）, IVB103 Injection（High dose）
- Where
- China
- Volunteers
- 18 people
- Sponsor
- InnoVec Biotherapeutics Inc.
Neovascular Age-related Macular Degeneration
Safety and Efficacy of ADVM-022 in Treatment-Experienced Patients With Neovascular Age-related Macular Degeneration [LUNA]
Neovascular or wet age-related macular degeneration (nAMD) is a degenerative ocular disease associated with the infiltration of abnormal blood vessels in the retina from the underlying choroid layer and is a leading cause of…
- Trial name
- NCT05536973
- Testing
- ADVM-022
- Where
- 39 sites in United States, France and 1 more
- Volunteers
- 69 people
- Sponsor
- Adverum Biotechnologies, Inc.
Neovascular Age-related Macular Degeneration (nAMD)
Study to Evaluate the Safety and Effectiveness of Intravitreal Injections (IVI) of Brolucizumab in Patients With Neovascular Age-related Macular Degeneration (nAMD)
The purpose of this study was to generate additional safety and effectiveness data in Indian neovascular age-related macular degeneration (nAMD) patients that more closely resemble the real-world population intended to be treated…
- Trial name
- NCT05269966
- Testing
- Injection Brolucizumab
- Where
- 10 sites in India
- Volunteers
- 105 people
- Sponsor
- Novartis Pharmaceuticals
Neovascular Age-related Macular Degeneration
Trial to Evaluate the Safety and Tolerability of Repeated Intravitreal Injection of IBI302 in Neovascular AMD Patients
This study is designed for multi-center, open-label, randomized, dose escalation phase I trial to evaluate the safety and tolerability of a multiple dose intravitreal injection of IBI302 in neovascular AMD patients.
- Trial name
- NCT04370379
- Testing
- IBI302 (the first dose level), IBI302 (the second dose level), Aflibercept
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.